Gilead Sciences Inc
A Look at Sarepta Therapeutics’ Stock Performance
After its stellar rise from $54.02 on January 8 to a high of $161.51 on September 28, Sarepta stock has seen selling pressure amid the market volatility in October.
How Vertex’s Revenue and Earnings Surprised in 2Q16
Vertex Pharmaceuticals (VRTX) reported its 2Q16 earnings on July 27, 2016. VRTX surpassed Wall Street analysts’ projections and reported revenue of $431.6 million.
Could Gilead Sciences’ Biktarvy Witness Solid Growth in 2018?
In February 2018, the US FDA approved Gilead Sciences’ Biktarvy for the treatment of individuals with HIV-1 infection.
How Gilead Sciences’ Gross Margin Outshines Its Peers
Despite a year-over-year (or YoY) drop in revenues in 2Q16, Gilead Sciences (GILD) managed to earn gross margins of about 92%.
What Analysts Project for Eli Lilly in 3Q17
For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.
Regeneron Continues to Trade at Premium
Regeneron is consistently trading at a premium compared to its peers. As of January 22, it was trading at a valuation multiple of 26.67x its earnings.
Amgen Continues to Control Operating Expenses in 3Q15
In 3Q15, Amgen recorded total operating expenses of ~$3.4 billion. This fall in expenses enabled the company to report a net profit margin of ~36.4%.
Alexion Pharmaceuticals Adds Metabolic Drug Kanuma to Portfolio
Kanuma was acquired by Alexion Pharmaceuticals on completion of the acquisition of Synageva Pharmaceuticals in June 2015.
Must-Read: Amgen’s 3Q15 Earnings and Conference Call
In its 3Q15 earnings report released on October 28, Amgen reported YoY revenue growth of ~14.0%, from $5.0 billion in 3Q14 to $5.7 billion in 3Q15.
Analysts Expect Biogen’s Net Profit Margins to Rise in 3Q15
Biogen’s (BIIB) 3Q15 earnings results will be announced on October 21, 2015. Analysts expect that the company will report lower net profit margins as compared to 2Q15.
How Vertex Pharmaceuticals’ Drugs Performed in 1Q18
In 1Q18, Vertex Pharmaceuticals’ (VRTX) Orkambi revenue rose ~20% YoY (year-over-year) to $354 million from $295 million.
AbbVie’s Viekira Pak Saw Weaker-than-Expected Performance
Viekira Pak managed to earn revenues worth about $414 million in 1Q16. The drug’s sales in the US market, however, fell YoY (year-over-year) by about 9.3% and reached $125 million in 1Q16.
Third Point Partners ups stake in Amgen
The fund noted in its letter that “Amgen has all the hallmarks of a hidden value situation, which is one of the fund’s favorite investment themes.”
Why Incyte Stock Fell ~9% on April 24
On April 24, Incyte (INCY) stock fell ~9% on news regarding its drug Baricitinib, which is under FDA review.
Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses
Sangamo Therapeutics (SGMO) stock rose ~16% in afternoon trading. SGMO released its Q2 earnings results on August 8 after the market closed.
Inside Alexion’s Metabolic Drugs Kanuma and Strensiq
In 1Q16, Strensiq added $33.2 million to Alexion Pharmaceuticals’ top line. Now the drug is in its initial launch phase in the US, Germany, and Japan.
Gilead Sciences’ Product Line Extension
As part of its significant product line extension, Gilead Sciences (GILD) is entering therapeutic areas such as oncology, pulmonology, and cardiology.
AbbVie Hopes to Commercialize Next-Generation HCV Regimen by 2017
AbbVie (ABBV) plans to complete its Phase 3 registrational program for investigational next-generation Hepatitis C virus (or HCV) therapy by 2016.
Gilead Sciences Stock Performance in 1Q18
Wall Street analysts estimate that Gilead Sciences (GILD) stock has the potential to return 21.1% over the next 12 months.
Biogen Trades at High Valuation Multiples Due to Strong Research Pipeline
After the release of its 3Q15 earnings results on October 21, Biogen was trading at PE multiples in the range of 13.8x–15.3x.
Johnson & Johnson Stock Remained Neutral to 2Q15 Earnings
Due to the decelerating revenue growth over all segments, Johnson & Johnson (JNJ) reported a decrease in its top line by ~8.8% in its 2Q15 earnings release on July 14, 2015.
How Could TAF-Based Regimen Drive Gilead Sciences’s Growth?
Gilead Sciences’s (GILD) TAF-based (tenofovir alafenamide) regimen comprises three products: Genvoya, Descovy, and Odefsey.
BioMarin’s Disappointing 3Q16 Earnings
BioMarin Pharmaceutical (BMRN) reported its 3Q16 earnings on October 27, 2016. Revenues were $279.9 million, which was lower than Wall Street analysts’ projections.
AbbVie Strengthens Its Position in the Virology Segment
In addition to Humira, AbbVie also offers several virology drugs targeting diseases such as hepatitis C, HIV, and respiratory syncytial virus.
What’s Gilead Sciences’ Valuation?
Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.
How Kanuma’s Addition to Alexion’s Portfolio Impacts Its Earnings
Alexion added Kanuma to its portfolio in 2015 after its Synageva acquisition. But ALXN didn’t have much time to build diagnostics as it did with Strensiq.
Medicaid Restrictions Are Affecting Gilead’s Hepatitis C Drug Sales
Since the launch of Sovaldi in late 2013, Gilead Sciences has managed to treat about 1,000,000 hepatitis C (or HCV) patients globally.
What Else Could Drive Gilead’s Long-Term Growth?
In December 2017, Kite, a Gilead Sciences (GILD) company, presented long-term follow-up data from its pivotal ZUMA-1 trial of Yescarta.
Allergan’s 1Q18 Earnings: Analysts’ Estimates
Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.
FDA Granted Breakthrough Therapy Status to Merck’s HCV Therapy
The U.S. Food and Drug Administration (or FDA) granted breakthrough therapy designation to Merck’s (MRK) grazoprevir/elbasvir (100mg/50mg) combination therapy.
Why Sangamo Therapeutics Stock Is Down More than 22% Today
Today, Sangamo Therapeutics (SGMO) stock is down over 22% in afternoon trading. Yesterday, SGMO stock closed at $19.05.
Pfizer Has Received Commercial Rights for Cresemba in Europe
On June 14, 2017, Pfizer (PFE) announced an agreement with Basilea Pharmaceutica for exclusive commercial rights for Cresemba in Europe.
Understanding Johnson & Johnson’s Ownership Structure
As of January 2015, Johnson & Johnson’s ownership structure is dominated by passive investments. They account for more than 80% of the total ownership structure.
FDA Approves Gilead's COVID-19 Drug Remdesivir, Stock Reacts
Gilead Sciences’ COVID-19 Drug Shows Promise
Today at 7:55 AM ET, Gilead Sciences stock rose by 3.9% to $75.99 in the pre-market session. The company’s remdesivir drug might treat COVID-19.
Norway’s Top Bank Scoops Up More Apple Stock
Apple stock has emerged as investors’ darling in the technology sector this year, with investors piling into AAPL in recent months.
Gilead Sciences’ Valuation Continues to Lag behind Peers
Post 2014, Gilead Sciences has traded at lower valuation multiples, as investors are uncertain of the company’s ability to continue its leadership in the global HIV market.
Analysts Recommendations for AbbVie in August 2017
Twenty-one analysts were tracking AbbVie in August 2017. Three analysts suggested a “strong buy,” while seven suggested a “buy.”
What Do Analysts Recommend for AbbVie?
Analysts updated their recommendations for AbbVie (ABBV) after the release of its 1Q16 earnings on April 28, 2016.
How’s Gilead Sciences Expected to Perform in 2016?
Gilead Sciences lowered its guidance for fiscal 2016 due to weak 2Q16 results reported on July 25. It expects its 2016 revenues to be $29.5 billion–$30.5 billion.
What Biogen Is Doing that Put It in Good Favor with Analysts
Based on recommendations from 25 broker companies, a Bloomberg survey reported that 62.5% of analysts gave Biogen (BIIB) “buy” recommendations.
Baxalta in the XBI Top Ten Large Caps
Baxalta (BXLT) rose by 6.2% for the week ending October 16, 2015. The stock rose as it received the Health Canada Approval for OBIZUR.
Gilead Sciences in 4Q15: Analysts Project Modest Revenue Growth
On February 02, 2016, Gilead Sciences will announce its 4Q15 earnings for the period ending December 31, 2015. Analysts expect modest revenue growth.
What Drove Gilead Sciences’ Hepatitis C Portfolio in 3Q15?
Gilead Sciences’ (GILD) hepatitis C (or HCV) portfolio is expected to continue driving the company’s revenues and net profit margins in 3Q15.
Incyte Was a Star Performer from August 10–17, 2015
By market cap size, Incyte (INCY) is among the top ten holdings of the SPDR S&P Biotech ETF (XBI). Incyte has a weight of 1.22% in XBI’s portfolio.
Celgene’s Operating Expenses in 3Q15
In 3Q15, Celgene’s gross profit margin improved due to a favorable product mix composed mainly of Revlimid, Pomalyst, and Otezla.
Abbvie Up over 6% on 1Q18 Earnings Beat, Raised Earnings Forecast
AbbVie (ABBV) released its 1Q18 earnings results for the quarter that ended on March 31 today.
Inside AbbVie’s Analyst Recommendations in 2016
Based on 24 recommendations, Bloomberg reported that 59.1% of analysts gave AbbVie a “buy” recommendation, while 36.4% of analysts gave the stock a “hold.”
Celgene Estimates Robust Revenue in 2017
In 2017, Celgene (CELG) expects to earn revenues of $13.0 billion–$13.4 billion, which would be a YoY (year-over-year) growth of around 18.0%.
BeiGene’s Q2 2018 Earnings: Reports Revenue Growth
BeiGene (BGNE) released its Q2 2018 earnings on August 9. BGNE surpassed analysts’ estimates for revenues but missed its EPS estimates.
Gilead Stock Falls, Coronavirus Drug Fails in Trial
Today at 6:07 AM ET, Gilead Sciences stock fell 1.4% to $76.70 in the pre-market session. According to reports, remdesivir failed its first clinical trial.
Will Johnson & Johnson’s Q1 Earnings Improve?
Johnson & Johnson (NYSE:JNJ) stock has declined by 3.2% since the beginning of 2020. However, the stock has fared better than the broader market.
The Baupost Group ups its stake in Idenix Pharmaceuticals
Idenix Pharmaceuticals (IDIX) accounted for a 6.25% position in Baupost’s fourth quarter portfolio. The hedge fund increased its stock holdings in Idenix last month.
Let’s Explore How Cost Leadership Provides Market Control
The attribute of “cost advantage” is the second most frequent source of economic moat ratings according to Morningstar. Companies that are able to produce and offer products or services at lower costs than competitors are often able to achieve much higher profit margins. Within many industries, cost leaders have a distinct competitive advantage and often […]
Why Durect Corporation Is Soaring Today
On July 22, Durect Corporation (DRRX) entered into a collaboration with HIV leader Gilead Sciences (GILD).
Gilead Sciences Expands Collaboration with Galapagos
On July 14, Gilead Sciences announced that it will expand its collaboration with Galapagos (GLPG).
What Are Gilead Sciences’ Key Growth Drivers in Fiscal 2019?
TAF-based HIV therapy Biktarvy and cell therapy Yescarta emerged as the key growth drivers for Gilead Sciences (GILD) in the first quarter. Besides these drugs, the company also expects HIV PrEP (pre-exposure prophylaxis therapies) Truvada and Descovy to be its key growth drivers in the future quarters.
How Are Gilead Sciences’ Revenues Trending in 2019?
In its first-quarter earnings investor presentation, Gilead Sciences (GILD) has projected fiscal 2019 product sales of $21.30 billion to $21.80 billion. Wall Street analysts have forecasted the company’s fiscal 2019 revenues to be $22.05 billion, a YoY decline of 0.36%.
What Are Analysts Recommending for Johnson & Johnson and Gilead?
Johnson & Johnson (JNJ) is up by 10.10%, and Gilead Sciences (GILD) is up by 10.92% on a YTD basis. Both the companies are struggling due to intense competitive pressures either from branded or generic competitors. The consensus recommendation for both Johnson & Johnson and Gilead Sciences is a “buy.”
What to Expect from Johnson & Johnson and Gilead Sciences’ EPS
In its first-quarter earnings press release, Johnson & Johnson (JNJ) has increased its fiscal 2019 adjusted diluted operational EPS guidance from the previously projected $8.65 to $8.80, which implies YoY growth of 5.7%–7.6%, to $8.73–$8.83, which implies a YoY rise of 6.7%–7.9%. The company also increased the lower end and narrowed its fiscal 2019 adjusted diluted EPS guidance from $8.50–$8.65.
How JNJ and Gilead Are Working to Expand Their Portfolios
According to Johnson & Johnson’s first-quarter earnings conference call, Erleada gained a four-percentage-point market share in the US on a YoY basis. The drug is now being prescribed equally by urologists and well as oncologists, the two key prescribers for prostate cancer drugs.
Biktarvy to Have Strong International Revenue Performance
Gilead Sciences (GILD) had launched Biktarvy in 19 European markets by the end of the first quarter.
What Seattle Genetics’ Bottom-Line Trend Indicates
In December 2018, of the total 13 analysts covering Seattle Genetics, eight analysts have given Seattle Genetics stock a “buy” or higher rating.
How’s Seattle Genetics Positioned?
Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.
Taking Stock of Sangamo’s Financial Performance
In this series, we explore Sangamo’s financials, analysts’ views on the stock, and the company’s valuation metrics.
United Therapeutics: Recent Developments and Analysts’ Ratings
On November 15, United Therapeutics (UTHR) entered into a global license agreement with Arena Pharmaceuticals (ARNA).
Gilead Sciences: Analysts’ Recommendations
In November, six analysts recommended a “strong buy,” ten recommended a “buy,” and 12 recommended a “hold” for Gilead Sciences.
Analysts Expect Incyte to Report Revenue Growth in Third Quarter
Analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018.
A Performance Overview of JNJ’s Imbruvica, Velcade, and Zytiga
Johnson & Johnson’s (JNJ) Imbruvica generated revenue of $705.0 million in the third quarter.
Amgen: Expect Nearly Flat Revenues in Q3
New products are expected to deliver double-digit growth, while legacy brands are expected to offset the growth during the quarter.
Allergan’s Q3 2018 Estimates: Revenue Decline Expected
Analysts are estimating that Allergan’s (AGN) third-quarter revenues will decline 3.8% to $3.88 billion.
Biogen: Analysts’ Recommendations on October 19
For Biogen, eight analysts recommended a “strong buy,” 12 recommended a “buy,” and nine recommended a “hold.”
Analyzing Sarepta’s Product Pipeline
Sarepta is expected to incur R&D expenses of $277.8 million in fiscal 2018, compared with $166.71 million in fiscal 2017.
Celgene’s Financial Position before Its Third-Quarter Earnings
Celgene is expected to report its third-quarter earnings on October 25. Celgene is expected to generate revenues of $3.8 billion in the third quarter.
Cara Therapeutics: Performance and Estimates for Q3
Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017.
Analyzing Gilead Sciences’ Research Pipeline Developments
On October 3, Gilead Sciences (GILD) reported the results from a phase three study evaluating Biktarvy’s safety and efficacy.
Allergan’s Stock Performance and Estimates for Q3 2018
Wall Street analysts expect Allergan to report EPS of $3.98 on revenues of $3.8 billion in the third quarter.
Eli Lilly’s Earnings Quality and Dividend Performance
Eli Lilly’s dividend yield is 2.11%. Its dividend yield last year was 2.46%, and its five-year average is 2.77%.
How GlaxoSmithKline Stock Has Performed in September
Analyst estimates suggest GlaxoSmithKline stock could rise ~6.3% over the next 12 months.
Allergan’s SpotLyte and Lumivive System
SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.
Here Are the Key Products in Sage’s GABA Receptor Portfolio
Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders.
Shire’s Quarterly Revenue Trend
Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter.
Delstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio
Gilead Sciences’ Atripla, Genvoya, and Stribild generated revenues of $663.0 million, $2.2 billion, and $361.0 million, respectively, in the first half of 2018.
Estimates and Recommendations for Bluebird Bio on September 6
Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017.
An Overview of Roche’s Hemato-Oncology Drugs MabThera and Gazvya
Roche’s (RHHBY) MabThera/Rituxan reported revenues of 3.45 billion Swiss francs in the first half compared to 3.8 billion Swiss francs in the first half of 2017.
Examining Amgen’s Revenue Trend in Q2 2018
Amgen reported a 4% rise in its year-over-year revenue to ~$6.06 billion in the second quarter compared to $5.81 billion in the first quarter of 2017.
Considering Allergan’s Q2 2018 Revenue Trend
As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter.
Analyst Recommendations for Biogen and Its Peers in August
On July 25, Biogen (BIIB) and Eisai announced positive results from the Phase 2 study evaluating BAN2401 in early Alzheimer’s disease.
What Analysts Recommend for Ionis after Q2 2018
Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017.
Analysts Have Mixed Opinions about Ionis
Wall Street analysts estimate that Ionis’s (IONS) Q2 2018 revenues will rise ~30.0% to $135.5 million as compared to $104.2 million in Q2 2017.
Why Editas Medicine Stock Fell in July
Editas Medicine’s (EDIT) general and administrative expenses are expected to rise 39.57% year-over-year in the second quarter.
Incyte’s Q2 2018 Earnings Beat Analysts’ Revenue Estimates
Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018.
What to Expect from Shire’s Q2 2018 Earnings on July 31
Shire (SHPG) is set to release its Q2 2018 earnings on July 31. Wall Street analysts expect EPS of $3.67 on revenues of $3.8 billion.
PTC Therapeutics to Acquire Agilis Biotherapeutics
On July 19, PTC Therapeutics (PTCT) agreed to acquire Agilis Biotherapeutics. The acquisition is expected to close during Q3 2018.
Sage Therapeutics’ GABA Receptor–Based Products
On June 12, Sage Therapeutics announced its expedited development plan for SAGE-217.
Amgen Announced the Phase 3 Results for ABP 710
On June 27, Amgen (AMGN) announced the top-line results for the NCT02937701 study—a Phase 3 study evaluating safety and efficacy of ABP 710.
How the Healthcare Sector’s Dividend Yield Stacks Up
The healthcare industry has an average dividend yield of 1.9%.
Viking Therapeutics Stock Rose 101% on May 31
On May 31, Viking Therapeutics (VKTX) closed at $9.99—a rise of ~101% from the previous day’s closing price of $4.97.
What Led to MEI Pharma Stock’s 55% Rise Last Week?
MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18.
A Look at Gilead Sciences’ Financial Performance
Gilead Sciences’ (GILD) total revenues decreased from $6.5 billion in Q1 2017 to $5.1 billion in Q1 2018 due to lower product sales.